Wellbutrin (bupropion) is not FDA-approved for treating anxiety disorders. Its only approved use is for major depressive disorder. However, it is sometimes prescribed off-label for anxiety symptoms, and the clinical picture is more nuanced than a simple yes or no. Depending on the situation, Wellbutrin can help reduce anxiety, have no effect on it, or actually make it worse.
What Wellbutrin Is Approved For
The FDA has approved Wellbutrin solely for the treatment of major depressive disorder. No anxiety disorder, whether generalized anxiety, social anxiety, or panic disorder, appears on its list of approved indications. This stands in contrast to several SSRIs (selective serotonin reuptake inhibitors), which carry FDA approval for multiple anxiety conditions in addition to depression.
That said, “not FDA-approved for anxiety” doesn’t mean it never helps with anxiety. It means the drug hasn’t gone through the specific regulatory process required to earn that label. Prescribers can and do use it off-label when they believe it fits a patient’s profile.
How It Works Differently Than SSRIs
Most medications commonly prescribed for anxiety disorders work by boosting serotonin levels in the brain. SSRIs like sertraline and escitalopram do exactly that. Wellbutrin takes a completely different approach. It increases the activity of two other brain chemicals: dopamine and norepinephrine. It has virtually no effect on serotonin, even at high doses.
This distinction matters because serotonin-based treatments have the strongest track record for standalone anxiety disorders. Wellbutrin’s dopamine and norepinephrine activity can boost motivation, energy, and focus, which is why it’s a popular choice for depression that involves fatigue and low drive. But that same stimulating quality is also why it can feel activating in a way that doesn’t always mix well with anxiety.
What the Research Actually Shows
Here’s where things get interesting. A large meta-analysis pooling individual patient data from 10 double-blind clinical trials found that Wellbutrin reduced anxiety symptoms just as effectively as SSRIs in people being treated for depression. Both drug classes produced nearly identical improvements on standardized anxiety scales, and the improvements happened on the same timeline. Among patients whose depression fully remitted, about the same percentage in each group still had some leftover anxiety symptoms afterward.
The catch is that this evidence comes specifically from people with depression who also had anxiety symptoms, not from people with a primary anxiety disorder like generalized anxiety or panic disorder. Roughly half of all outpatients with major depression also carry a significant burden of anxiety, so this overlap is extremely common. But there’s very little research on Wellbutrin for anxiety disorders on their own, without depression in the picture. That gap in the research is a big reason it hasn’t earned an FDA indication for anxiety.
Clinicians themselves reflect this uncertainty. Surveys show that doctors are less likely to choose Wellbutrin over SSRIs when a depressed patient’s anxiety symptoms are particularly prominent, even though the head-to-head data suggests comparable results.
The Risk of Increased Anxiety
One of the most important things to know about Wellbutrin is that it can temporarily increase anxiety, especially in the early weeks of treatment. In clinical trials, about 32% of people taking Wellbutrin reported agitation (compared to 22% on placebo), and 21% experienced tremor (versus about 8% on placebo). Anxiety as a specific side effect was reported by around 3% of patients, roughly triple the placebo rate.
The prescribing label puts it plainly: a substantial proportion of patients experience some degree of increased restlessness, agitation, anxiety, and insomnia, particularly shortly after starting the medication. For most people, these effects are manageable and tend to settle down. In about 2% of patients, the activation symptoms are severe enough that the medication has to be stopped.
This early-phase anxiety tends to be more pronounced in people who already have significant anxiety before starting the drug. If you have panic attacks, this is especially relevant. Wellbutrin’s stimulating profile can potentially trigger or worsen panic symptoms, and prescribers generally approach it with extra caution in that population.
When Prescribers Choose Wellbutrin for Anxious Patients
Despite the caveats, there are specific scenarios where Wellbutrin makes sense for someone dealing with both depression and anxiety. SSRIs, while effective for anxiety, come with side effects that some people find intolerable: sexual dysfunction, weight gain, and emotional blunting are common complaints. Wellbutrin is far less likely to cause any of these. For someone who tried an SSRI and stopped because of those side effects, Wellbutrin offers a meaningfully different experience.
Wellbutrin is also sometimes paired with an SSRI rather than used alone. In this combination, the SSRI handles anxiety while Wellbutrin counteracts some of the SSRI’s side effects (particularly sexual dysfunction and fatigue) and adds extra antidepressant coverage. This is a common strategy, though combining the two can potentially increase the risk of seizures and may amplify stimulation-related side effects like tremor and anxiety in some individuals.
Anxiety From Depression vs. an Anxiety Disorder
The answer to whether Wellbutrin helps with anxiety depends heavily on where the anxiety is coming from. Depression and anxiety are deeply intertwined. When depression lifts, the anxiety that came with it often improves too, regardless of which antidepressant did the lifting. The clinical trial data showing Wellbutrin matches SSRIs for anxiety likely reflects this dynamic: treat the depression successfully, and the co-occurring anxiety follows.
If your anxiety exists independently of depression, or if you have a diagnosed anxiety disorder like generalized anxiety, social anxiety, or panic disorder, the evidence base for Wellbutrin is much thinner. SSRIs and SNRIs remain the first-line medications for these conditions, backed by decades of clinical trials designed specifically around anxiety outcomes. Wellbutrin simply hasn’t been studied the same way for those diagnoses, so prescribers have far less data to work with when considering it as a primary anxiety treatment.